Trastuzumab

SAN ANTONIO — The addition of atezolizumab to chemotherapy, trastuzumab and pertuzumab did not significantly increase pathologic complete response rates among women with HER2-positive breast cancer.

Precision oncology therapies requiring biomarker testing comprised 43% of all FDA oncology drug approvals between 1998 and 2022, study results published in Cancer Discovery showed.

The FDA revised an existing indication of pembrolizumab for the first-line treatment of certain patients with gastric or gastroesophageal junction adenocarcinoma.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about current and emerging prognostic biomarkers of endometrial cancer.

CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.

CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.

The FDA announced several regulatory actions the past few weeks.

Adjuvant paclitaxel and trastuzumab continued to appear effective after 10 years of follow up among patients with small node-negative, HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

Updated data from a randomized phase 3 study showed a pertuzumab-based regimen continued to provide durable benefit for people with HER2-positive early breast cancer, according to the agent’s manufacturer.

A combination of nivolumab, trastuzumab and chemotherapy prolonged PFS and OS among patients with previously untreated, metastatic ERBB2-positive esophagogastric cancer, according to study results published in JAMA Oncology.